Vintermyr OK, et al. - In a routine screening population, researchers determined the prevalence of clinically relevant HPV types and their specific risk for progression and regression in women with atypical squamous cells of uncertain significance (ASCUS) and low-grade squamous intraepithelial lesions (LSIL). The CIN2+ progression risk for all HPV 16, all HPV 35, single HPV 16 and single HPV 35 infections were noted to be 65.3%, 64.4%, 63.8% and 73.7%, respectively. Four main groups were identified on the basis of CIN2+ progression risks; the HPV 16 group, the HPV 31/33/35 group, the HPV 18/45/51/52 group and the HPV 39/56/58/59/66/68 group with progression risks of 65.3%, 62.1%, 52.6 and 39.5 (95% CI: 33.0–46.0), respectively. Overall, a similar CIN2+ progression risk was reported for HPV types 16 and 35, including the HPV risk group 31/33/35. A higher risk for CIN3+ progression was noted only for HPV 16.